F8 and hemophilia: Therefore, we aimed at investigating the practice patterns of hemophilia treatment, bleeding rates, and the management of bleeding in a real-world cohort of persons with SHA and SHB, treated at a hemophilia center for adults in a Central European country between 2012 and 2017, a time period where most of the persons with hemophilia were receiving FVIII or FIX standard half-life concentrates.